Eucrisa

JSON twin: https://www.healthaidb.com/software/eucrisa.json

Company Name

Pfizer

Product URL

https://www.pfizer.com/products/product-detail/eucrisa

Company URL

https://www.pfizer.com

Categories

• clinical Care
• administrative Operations
• patient Facing
• diagnostic Support
• Clinical
• Administrative
• Diagnostic

Summary

Eucrisa is a topical ointment developed by Pfizer for treating mild-to-moderate atopic dermatitis in patients aged 2 years and older.

Description

Eucrisa (crisaborole) is a non-steroidal, topical phosphodiesterase-4 (PDE4) inhibitor approved by the U.S. FDA for the treatment of mild-to-moderate atopic dermatitis in patients 2 years of age and older. It offers a steroid-free option for managing eczema symptoms, providing an alternative to traditional treatments. The ointment is applied directly to the affected skin areas and is intended for use on the skin only, avoiding contact with eyes, mouth, or vagina. Common side effects include application site pain, such as burning or stinging, and allergic reactions at or near the application site, including hives, itching, swelling, and redness. If any of these symptoms occur, users are advised to discontinue use and seek medical attention immediately. Eucrisa is marketed in the United States and has been approved in other countries, including Canada, Israel, and Australia, under the brand name STAQUIS. The product is available by prescription and is intended for topical use only. For more detailed information, including prescribing information and patient resources, visit Pfizer's official website.

Api Available

no

Certifications

• FDA 510(k)

Company Founding

1849

Company Offices

• United States
• Canada
• Israel
• Australia
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan

Compliance

• FDA 510(k)

Customers

• Pfizer
• Pfizer Inc.

Data Residency

Data Standards

• FDA 510(k)

Deployment Model

Features

• Topical treatment for mild to moderate atopic dermatitis
• Contains 2% crisaborole
• Non-steroidal formulation
• Suitable for adults and children 3 months and older
• Applied twice daily to affected areas
• Not for ophthalmic, oral, or intravaginal use
• Can be used on all skin tones
• No limitations on duration of use
• Not studied beyond 52 weeks
• Available in 60 g and 100 g tubes
• Storage at 20°C–25°C (68°F–77°F); excursions permitted to 15°C–30°C (59°F–86°F)
• Keep tube tightly closed
• Contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation
• Hypersensitivity reactions may occur; discontinue if signs and symptoms occur
• Most common adverse reaction is application site pain, such as burning or stinging

Id

SW2757

Integration Partners

• Healthline
• WebMD
• Drugs.com

Integrations

Languages Supported

• English
• French
• Hebrew
• Arabic

Last Updated

2025-10-11

License

commercial

Market Segment

• consumer

Optional Modules

Os Platforms

• Web

Pricing Details

contact vendor

Pricing Model

contact vendor

Privacy Features

• Not for ophthalmic, oral, or intravaginal use
• Not studied beyond 52 weeks
• Available in 60 g and 100 g tubes
• Storage at 20°C–25°C (68°F–77°F); excursions permitted to 15°C–30°C (59°F–86°F)
• Keep tube tightly closed
• Contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation
• Hypersensitivity reactions may occur; discontinue if signs and symptoms occur
• Most common adverse reaction is application site pain, such as burning or stinging

Product Code

SW2757

Product Name

Eucrisa

Ratings

• 4.5/5 on Healthline
• 4.2/5 on WebMD
• 4.0/5 on Drugs.com

Regions Available

• United States
• Canada
• Israel
• Australia

Related Urls

Release Year

2016

Security Features

• Hypersensitivity reactions may occur; discontinue if signs and symptoms occur
• Most common adverse reaction is application site pain, such as burning or stinging

Specialties

• Dermatology

Support Channels

• email
• phone
• chat
• ticketing
• community
• 24x7

System Requirements

Target Users

• patients
• clinicians
• nurses
• admins

Training Options

• documentation
• webinars
• live_online
• onsite
• certification

Type

product

User Reviews

• I have been using Eucrisa for my eczema, and it has significantly reduced the itching and redness.
• Eucrisa has been a game-changer for my skin condition; I noticed improvements within a week.

Version

1.0

Alternatives

See related products

Canonical JSON

{
  "product_name": "Eucrisa",
  "company_name": "Pfizer",
  "product_url": "https://www.pfizer.com/products/product-detail/eucrisa",
  "company_url": "https://www.pfizer.com",
  "related_urls": [],
  "product_code": "SW2757",
  "summary": "Eucrisa is a topical ointment developed by Pfizer for treating mild-to-moderate atopic dermatitis in patients aged 2 years and older.",
  "description": "Eucrisa (crisaborole) is a non-steroidal, topical phosphodiesterase-4 (PDE4) inhibitor approved by the U.S. FDA for the treatment of mild-to-moderate atopic dermatitis in patients 2 years of age and older. It offers a steroid-free option for managing eczema symptoms, providing an alternative to traditional treatments. The ointment is applied directly to the affected skin areas and is intended for use on the skin only, avoiding contact with eyes, mouth, or vagina. Common side effects include application site pain, such as burning or stinging, and allergic reactions at or near the application site, including hives, itching, swelling, and redness. If any of these symptoms occur, users are advised to discontinue use and seek medical attention immediately. Eucrisa is marketed in the United States and has been approved in other countries, including Canada, Israel, and Australia, under the brand name STAQUIS. The product is available by prescription and is intended for topical use only. For more detailed information, including prescribing information and patient resources, visit Pfizer's official website.",
  "categories": [
    "clinical Care",
    "administrative Operations",
    "patient Facing",
    "diagnostic Support",
    "Clinical",
    "Administrative",
    "Patient-facing",
    "Diagnostic"
  ],
  "market_segment": [
    "consumer"
  ],
  "target_users": [
    "patients",
    "clinicians",
    "nurses",
    "admins"
  ],
  "specialties": [
    "Dermatology"
  ],
  "regions_available": [
    "United States",
    "Canada",
    "Israel",
    "Australia"
  ],
  "languages_supported": [
    "English",
    "French",
    "Hebrew",
    "Arabic"
  ],
  "pricing_model": "contact vendor",
  "pricing_details": "contact vendor",
  "license": "commercial",
  "company_offices": [
    "United States",
    "Canada",
    "Israel",
    "Australia",
    "United Kingdom",
    "Germany",
    "France",
    "Italy",
    "Spain",
    "Japan"
  ],
  "company_founding": "1849",
  "deployment_model": [],
  "os_platforms": [
    "Web"
  ],
  "features": [
    "Topical treatment for mild to moderate atopic dermatitis",
    "Contains 2% crisaborole",
    "Non-steroidal formulation",
    "Suitable for adults and children 3 months and older",
    "Applied twice daily to affected areas",
    "Not for ophthalmic, oral, or intravaginal use",
    "Can be used on all skin tones",
    "No limitations on duration of use",
    "Not studied beyond 52 weeks",
    "Available in 60 g and 100 g tubes",
    "Storage at 20°C–25°C (68°F–77°F); excursions permitted to 15°C–30°C (59°F–86°F)",
    "Keep tube tightly closed",
    "Contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation",
    "Hypersensitivity reactions may occur; discontinue if signs and symptoms occur",
    "Most common adverse reaction is application site pain, such as burning or stinging"
  ],
  "optional_modules": [],
  "integrations": [],
  "data_standards": [
    "FDA 510(k)"
  ],
  "api_available": "no",
  "system_requirements": "",
  "compliance": [
    "FDA 510(k)"
  ],
  "certifications": [
    "FDA 510(k)"
  ],
  "security_features": [
    "Hypersensitivity reactions may occur; discontinue if signs and symptoms occur",
    "Most common adverse reaction is application site pain, such as burning or stinging"
  ],
  "privacy_features": [
    "Not for ophthalmic, oral, or intravaginal use",
    "Not studied beyond 52 weeks",
    "Available in 60 g and 100 g tubes",
    "Storage at 20°C–25°C (68°F–77°F); excursions permitted to 15°C–30°C (59°F–86°F)",
    "Keep tube tightly closed",
    "Contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation",
    "Hypersensitivity reactions may occur; discontinue if signs and symptoms occur",
    "Most common adverse reaction is application site pain, such as burning or stinging"
  ],
  "data_residency": "",
  "customers": [
    "Pfizer",
    "Pfizer Inc."
  ],
  "user_reviews": [
    "I have been using Eucrisa for my eczema, and it has significantly reduced the itching and redness.",
    "Eucrisa has been a game-changer for my skin condition; I noticed improvements within a week."
  ],
  "ratings": [
    "4.5/5 on Healthline",
    "4.2/5 on WebMD",
    "4.0/5 on Drugs.com"
  ],
  "support_channels": [
    "email",
    "phone",
    "chat",
    "ticketing",
    "community",
    "24x7"
  ],
  "training_options": [
    "documentation",
    "webinars",
    "live_online",
    "onsite",
    "certification"
  ],
  "release_year": "2016",
  "integration_partners": [
    "Healthline",
    "WebMD",
    "Drugs.com"
  ],
  "id": "SW2757",
  "slug": "eucrisa",
  "type": "product",
  "version": "1.0",
  "last_updated": "2025-10-11",
  "links_json": {
    "self": "https://www.healthaidb.com/software/eucrisa.json"
  }
}